Rafferty Asset Management
JBIO

Rafferty Asset Management’s Jade Biosciences JBIO Stock Holding History

Rafferty Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$947K Buy
+42,629
New +$889K ﹤0.01% 794

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's JBIO Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Jade Biosciences (JBIO) in Q2 2026: 42,629 shares worth $947K. The stake represents ﹤0.01% of the portfolio and ranks #794 among its holdings.

154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Rafferty Asset Management held 42,629 shares of Jade Biosciences worth $947K as of Q2 2026.
  • Jade Biosciences was a new Rafferty Asset Management position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #794 holding.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.